<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132808</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446N2312</org_study_id>
    <nct_id>NCT00132808</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older</brief_title>
  <official_title>A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Osteoporosis prevention is important in patients with osteopenia (low bone density). This
      study will test the safety and efficacy of zoledronic acid in patients diagnosed with
      osteopenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum</measure>
    <time_frame>Baseline, Month 24</time_frame>
    <description>The percentage change in lumbar spine BMD at Month 24 relative to baseline was derived as 100 x (lumbar spine BMD at 24 Month - lumbar spine BMD at baseline) / (lumbar spine BMD at baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Hip BMD at Month 24 Relative to Baseline, by Stratum.</measure>
    <time_frame>Baseline, Month 24</time_frame>
    <description>The percentage change in total hip BMD at Month 24 relative to baseline was derived as 100 x (total hip BMD at 24 Month - total hip BMD at baseline) / (total hip BMD at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Femoral Neck BMD at Month 24 Relative to Baseline, by Stratum.</measure>
    <time_frame>Baseline, Month 24</time_frame>
    <description>The percentage change in femoral neck BMD at Month 24 relative to baseline was derived as 100 x (femoral neck BMD at 24 Month - femoral neck BMD at baseline) / (femoral neck BMD at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Marker of Bone Resorption: Serum Beta C-telopeptides (b-CTx), by Stratum</measure>
    <time_frame>Months 6, 12, 18 and 24</time_frame>
    <description>Biomarker: Serum b-CTx levels at Months 6, 12, 18 and 24 by stratum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Marker of Bone Formation: Serum N-terminal Propeptide of Type 1 Collagen (P1NP), by Stratum</measure>
    <time_frame>Months 6, 12, 18 and 24</time_frame>
    <description>Biomarker: Serum P1NP levels at Months 6, 12, 18 and 24 by stratum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Marker of Bone Formation: Bone Serum Alkaline Phosphatase (BSAP), by Stratum</measure>
    <time_frame>Months 6, 12, 18 and 24</time_frame>
    <description>Biomarker: BSAP levels at Months 6, 12, 18 and 24 by stratum.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">581</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Zoledronic Acid 2x5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoledronic Acid 1x5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given at randomization and Month 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>Zoledronic acid 5 mg intravenous</description>
    <arm_group_label>Zoledronic Acid 2x5 mg</arm_group_label>
    <arm_group_label>Zoledronic Acid 1x5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Physiologic 0.9% normal saline</description>
    <arm_group_label>Zoledronic Acid 1x5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal

          -  Greater than or equal to 45 years of age

          -  Osteopenia (lumbar spine bone mineral density [BMD] T-score between -1.0 and -2.5, and
             BMD T-score &gt; -2.5 at the femoral neck)

        Exclusion Criteria:

          -  Patients with more than one Grade 1 vertebral fracture (as per Genant method; patients
             with one Grade 1 vertebral fracture are eligible to participate)

          -  Patients with any Grade 2 or 3 vertebral fracture (as per Genant method)

          -  Patients with 25-(OH) vitamin D levels less than 15 ng/mL prior to randomization

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>For information regarding facilities, please contact the Central Contact</name>
      <address>
        <city>E. Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2005</study_first_submitted>
  <study_first_submitted_qc>August 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2005</study_first_posted>
  <results_first_submitted>December 10, 2010</results_first_submitted>
  <results_first_submitted_qc>December 10, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2011</results_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postmenopausal osteoporosis</keyword>
  <keyword>osteopenia</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>Osteopenia (osteoporosis prevention)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible patients were stratified according to their duration of menopause (those less than 5 years from menopause were included in Stratum I, while those 5 or more years from menopause were included in Stratum II), and randomized equally to one of the three treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid 2x5 mg</title>
          <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
        </group>
        <group group_id="P2">
          <title>Zoledronic Acid 1x5 mg</title>
          <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo given at randomization and Month 12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stratum I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result (s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Stratum II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid 2x5 mg</title>
          <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
        </group>
        <group group_id="B2">
          <title>Zoledronic Acid 1x5 mg</title>
          <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo given at randomization and Month 12</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
            <count group_id="B2" value="181"/>
            <count group_id="B3" value="202"/>
            <count group_id="B4" value="581"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Stratum I (Women &lt; 5 Years From Menopause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="3.62"/>
                    <measurement group_id="B2" value="53.7" spread="3.59"/>
                    <measurement group_id="B3" value="54.4" spread="3.83"/>
                    <measurement group_id="B4" value="53.9" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II (Women &gt;= 5 Years From Menopause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="6.62"/>
                    <measurement group_id="B2" value="63.4" spread="7.74"/>
                    <measurement group_id="B3" value="64.2" spread="7.65"/>
                    <measurement group_id="B4" value="63.8" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data presented for Overall number of Participants and Gender include participants from both strata of the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="202"/>
                    <measurement group_id="B4" value="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum</title>
        <description>The percentage change in lumbar spine BMD at Month 24 relative to baseline was derived as 100 x (lumbar spine BMD at 24 Month – lumbar spine BMD at baseline) / (lumbar spine BMD at baseline).</description>
        <time_frame>Baseline, Month 24</time_frame>
        <population>Intent to treat population. Last observation carried forward (LOCF) was utilized to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid 2x5 mg</title>
            <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid 1x5 mg</title>
            <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo given at randomization and Month 12</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum</title>
          <description>The percentage change in lumbar spine BMD at Month 24 relative to baseline was derived as 100 x (lumbar spine BMD at 24 Month – lumbar spine BMD at baseline) / (lumbar spine BMD at baseline).</description>
          <population>Intent to treat population. Last observation carried forward (LOCF) was utilized to impute missing data.</population>
          <units>Percentage change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stratum I (Women &lt; 5 Years From Menopause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" spread="0.444" lower_limit="5.77" upper_limit="7.96"/>
                    <measurement group_id="O2" value="4.03" spread="0.444" lower_limit="5.15" upper_limit="7.39"/>
                    <measurement group_id="O3" value="-2.24" spread="0.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II (Women &gt;= 5 Years From Menopause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.60" spread="0.343" lower_limit="5.32" upper_limit="7.17"/>
                    <measurement group_id="O2" value="4.76" spread="0.356" lower_limit="4.46" upper_limit="6.36"/>
                    <measurement group_id="O3" value="-0.65" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Total Hip BMD at Month 24 Relative to Baseline, by Stratum.</title>
        <description>The percentage change in total hip BMD at Month 24 relative to baseline was derived as 100 x (total hip BMD at 24 Month - total hip BMD at baseline) / (total hip BMD at baseline).</description>
        <time_frame>Baseline, Month 24</time_frame>
        <population>Intent to treat population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid 2x5 mg</title>
            <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid 1x5 mg</title>
            <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo given at randomization and Month 12</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Hip BMD at Month 24 Relative to Baseline, by Stratum.</title>
          <description>The percentage change in total hip BMD at Month 24 relative to baseline was derived as 100 x (total hip BMD at 24 Month - total hip BMD at baseline) / (total hip BMD at baseline).</description>
          <population>Intent to treat population with available data.</population>
          <units>Percentage change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stratum I (Women &lt; 5 Years From Menopause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.318" lower_limit="4.00" upper_limit="5.52"/>
                    <measurement group_id="O2" value="2.55" spread="0.317" lower_limit="3.86" upper_limit="5.43"/>
                    <measurement group_id="O3" value="-2.10" spread="0.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II (Women &gt;= 5 Years From Menopause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="0.265" lower_limit="3.36" upper_limit="4.80"/>
                    <measurement group_id="O2" value="2.11" spread="0.282" lower_limit="2.40" upper_limit="3.91"/>
                    <measurement group_id="O3" value="-1.04" spread="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Femoral Neck BMD at Month 24 Relative to Baseline, by Stratum.</title>
        <description>The percentage change in femoral neck BMD at Month 24 relative to baseline was derived as 100 x (femoral neck BMD at 24 Month - femoral neck BMD at baseline) / (femoral neck BMD at baseline).</description>
        <time_frame>Baseline, Month 24</time_frame>
        <population>Intent to treat population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid 2x5 mg</title>
            <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid 1x5 mg</title>
            <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo given at randomization and Month 12</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Femoral Neck BMD at Month 24 Relative to Baseline, by Stratum.</title>
          <description>The percentage change in femoral neck BMD at Month 24 relative to baseline was derived as 100 x (femoral neck BMD at 24 Month - femoral neck BMD at baseline) / (femoral neck BMD at baseline).</description>
          <population>Intent to treat population with available data.</population>
          <units>Percentage change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stratum I (Women &lt; 5 Years From Menopause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.550" lower_limit="2.27" upper_limit="4.90"/>
                    <measurement group_id="O2" value="2.01" spread="0.549" lower_limit="2.20" upper_limit="4.92"/>
                    <measurement group_id="O3" value="-1.55" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II (Women &gt;= 5 Years From Menopause)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.344" lower_limit="2.60" upper_limit="4.47"/>
                    <measurement group_id="O2" value="1.46" spread="0.366" lower_limit="1.67" upper_limit="3.62"/>
                    <measurement group_id="O3" value="-1.18" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Marker of Bone Resorption: Serum Beta C-telopeptides (b-CTx), by Stratum</title>
        <description>Biomarker: Serum b-CTx levels at Months 6, 12, 18 and 24 by stratum.</description>
        <time_frame>Months 6, 12, 18 and 24</time_frame>
        <population>Intent to treat population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid 2x5 mg</title>
            <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid 1x5 mg</title>
            <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo given at randomization and Month 12</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Marker of Bone Resorption: Serum Beta C-telopeptides (b-CTx), by Stratum</title>
          <description>Biomarker: Serum b-CTx levels at Months 6, 12, 18 and 24 by stratum.</description>
          <population>Intent to treat population with available data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stratum I - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2217" spread="0.11791"/>
                    <measurement group_id="O2" value="0.2286" spread="0.09630"/>
                    <measurement group_id="O3" value="0.6439" spread="0.27902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2861" spread="0.13776"/>
                    <measurement group_id="O2" value="0.3111" spread="0.13195"/>
                    <measurement group_id="O3" value="0.6634" spread="0.25433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2187" spread="0.16812"/>
                    <measurement group_id="O2" value="0.3605" spread="0.14847"/>
                    <measurement group_id="O3" value="0.6444" spread="0.28254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2864" spread="0.12242"/>
                    <measurement group_id="O2" value="0.3777" spread="0.14943"/>
                    <measurement group_id="O3" value="0.6640" spread="0.27538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1918" spread="0.12648"/>
                    <measurement group_id="O2" value="0.1888" spread="0.10625"/>
                    <measurement group_id="O3" value="0.5802" spread="0.25034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2696" spread="0.18247"/>
                    <measurement group_id="O2" value="0.2484" spread="0.11435"/>
                    <measurement group_id="O3" value="0.5634" spread="0.23442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1986" spread="0.14900"/>
                    <measurement group_id="O2" value="0.2854" spread="0.14391"/>
                    <measurement group_id="O3" value="0.5742" spread="0.24399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2554" spread="0.17049"/>
                    <measurement group_id="O2" value="0.3254" spread="0.15260"/>
                    <measurement group_id="O3" value="0.6012" spread="0.26942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Marker of Bone Formation: Serum N-terminal Propeptide of Type 1 Collagen (P1NP), by Stratum</title>
        <description>Biomarker: Serum P1NP levels at Months 6, 12, 18 and 24 by stratum.</description>
        <time_frame>Months 6, 12, 18 and 24</time_frame>
        <population>Intent to treat population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid 2x5 mg</title>
            <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid 1x5 mg</title>
            <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo given at randomization and Month 12</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Marker of Bone Formation: Serum N-terminal Propeptide of Type 1 Collagen (P1NP), by Stratum</title>
          <description>Biomarker: Serum P1NP levels at Months 6, 12, 18 and 24 by stratum.</description>
          <population>Intent to treat population with available data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stratum I - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.851" spread="9.7724"/>
                    <measurement group_id="O2" value="20.752" spread="9.7560"/>
                    <measurement group_id="O3" value="59.449" spread="20.3291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.231" spread="12.3748"/>
                    <measurement group_id="O2" value="30.500" spread="14.8217"/>
                    <measurement group_id="O3" value="55.166" spread="20.5274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.102" spread="12.6635"/>
                    <measurement group_id="O2" value="35.561" spread="14.1588"/>
                    <measurement group_id="O3" value="55.775" spread="19.8842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.288" spread="12.2706"/>
                    <measurement group_id="O2" value="38.743" spread="14.7626"/>
                    <measurement group_id="O3" value="56.315" spread="20.3715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.369" spread="14.1819"/>
                    <measurement group_id="O2" value="19.423" spread="16.6028"/>
                    <measurement group_id="O3" value="50.271" spread="22.6624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.333" spread="15.8193"/>
                    <measurement group_id="O2" value="26.363" spread="13.1112"/>
                    <measurement group_id="O3" value="49.581" spread="20.6559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.031" spread="14.8270"/>
                    <measurement group_id="O2" value="29.569" spread="14.7631"/>
                    <measurement group_id="O3" value="46.943" spread="18.8147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.211" spread="11.8566"/>
                    <measurement group_id="O2" value="34.418" spread="15.4474"/>
                    <measurement group_id="O3" value="51.621" spread="20.9281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Marker of Bone Formation: Bone Serum Alkaline Phosphatase (BSAP), by Stratum</title>
        <description>Biomarker: BSAP levels at Months 6, 12, 18 and 24 by stratum.</description>
        <time_frame>Months 6, 12, 18 and 24</time_frame>
        <population>Intent to treat population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid 2x5 mg</title>
            <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid 1x5 mg</title>
            <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo given at randomization and Month 12</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Marker of Bone Formation: Bone Serum Alkaline Phosphatase (BSAP), by Stratum</title>
          <description>Biomarker: BSAP levels at Months 6, 12, 18 and 24 by stratum.</description>
          <population>Intent to treat population with available data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stratum I - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.718" spread="2.5827"/>
                    <measurement group_id="O2" value="8.841" spread="2.2434"/>
                    <measurement group_id="O3" value="13.982" spread="4.7106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.945" spread="2.9027"/>
                    <measurement group_id="O2" value="10.539" spread="2.9800"/>
                    <measurement group_id="O3" value="14.127" spread="4.8981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.365" spread="2.5574"/>
                    <measurement group_id="O2" value="11.233" spread="3.1563"/>
                    <measurement group_id="O3" value="14.149" spread="4.8878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum I - Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.799" spread="2.5836"/>
                    <measurement group_id="O2" value="11.764" spread="3.8401"/>
                    <measurement group_id="O3" value="14.353" spread="4.9089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.219" spread="2.8126"/>
                    <measurement group_id="O2" value="7.925" spread="2.2847"/>
                    <measurement group_id="O3" value="13.394" spread="5.2169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.678" spread="3.0216"/>
                    <measurement group_id="O2" value="9.139" spread="2.4558"/>
                    <measurement group_id="O3" value="13.650" spread="4.8295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.357" spread="2.2152"/>
                    <measurement group_id="O2" value="10.023" spread="2.8237"/>
                    <measurement group_id="O3" value="13.222" spread="4.9167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stratum II - Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.730" spread="2.7591"/>
                    <measurement group_id="O2" value="10.916" spread="3.5878"/>
                    <measurement group_id="O3" value="13.902" spread="4.6302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid 2x5 mg</title>
          <description>Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12</description>
        </group>
        <group group_id="E2">
          <title>Zoledronic Acid 1x5 mg</title>
          <description>Zoledronic acid 5 mg i.v. given at randomization and placebo at Month 12</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo given at randomization and Month 12</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Loose body in joint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cardiac neoplasm unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Neurilemmoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial metaplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="160" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

